Press releases
You will be able to find all of our recent press releases. You can search by keyword or filter by year/business category to quickly find what you need.
You may also want to view our USA press releases and Asia press releases.
Press releases for our local operating companies can be viewed on our individual country websites.
Filter by
-
GSK receives positive top-line results from sirukumab phase III programme supporting regulatory filings for rheumatoid arthritis in 2016
GSK today announced it has received positive top-line results from the phase III programme invest...
Read more -
Comic Relief and GSK form five-year partnership to fight malaria and strengthen health systems
A five-year partnership to fight malaria and improve health in five countries worst affected by t...
Read more -
GSK receives European marketing authorisation for Nucala® (mepolizumab) in 31 countries
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the European Commission has granted marketin...
Read more -
GSK announces start of phase III study of sirukumab in Giant Cell Arteritis
GSK today announced that dosing has commenced in a phase III study evaluating sirukumab, a human ...
Read more -
GSK receives European marketing authorisation to expand indication for Volibris® in treatment of pulmonary arterial hypertension
GSK today announced that the European Commission has approved a variation to expand the current t...
Read more -
GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) administered subcutaneously in patients with systemic lupus erythematosus
GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) administere...
Read more -
GSK’s Nucala® (mepolizumab) receives approval from US FDA
First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic pheno...
Read more -
ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as sh...
Read more -
GSK and Merck to study immunotherapy combination as potential cancer treatment
Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in comb...
Read more -
GSK profiles innovative R&D portfolio to investors
40 potential new medicines and vaccines offer significant opportunity to drive long-term performa...
Read more -
Results announcement for the third quarter 2015
Q3 sees continued progress in execution of Group strategy Sales of £6.1 billion (+11% CER) and c...
Read more -
GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the second pivotal phase III study of it...
Read more -
GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study)
GSK today announced that, as per the stepwise trial design of its losmapimod phase III study, LAT...
Read more -
GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of patients with asthma
GlaxoSmithKline plc (GSK) today announced results from the ‘LABA’ (long acting beta2-agonist) saf...
Read more -
GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hypertension
GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hyper...
Read more -
GSK announces positive new data comparing Incruse® Ellipta® to tiotropium and glycopyrronium in patients with COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive results from two head-to-head studie...
Read more -
GSK submits regulatory application for chlorhexidine gel for the prevention of umbilical cord infections in newborn babies
GSK today announced that it has submitted a regulatory application to the European Medicines Agen...
Read more -
GSK presents post-hoc analysis of Anoro® Ellipta® data assessing markers of COPD deterioration compared to tiotropium or placebo using a novel composite endpoint
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced data presented by G...
Read more -
Regulatory update: GSK and Theravance announce intention to file Relvar® Ellipta® for COPD in Japan
GlaxoSmithKline (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the intention...
Read more -
GSK receives positive CHMP opinion in Europe for novel anti-IL5 biological Nucala (mepolizumab) for the treatment of patients with severe refractory eosinophilic asthma
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the Committee for Medicinal Products for Hum...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
-
Investors
Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting
